Skinvisible Pharmaceuticals, Inc. announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose- controlling drugs) including a GLP-1 agonist and CB-1 receptor antagonist delivered by its proprietary Invisicare technology; a polymer delivery vehicle that does not require a patch or needles. The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of obesity drugs and other glucose-controlling agents. The Company has been developing topical formulations to enable transdermal absorption of these drugs, allowing for sustained release into the bloodstream.

The results are compelling: Franz Cell diffusion studies demonstrated up to 69% penetration over six hours for the GLP-1 drug tested; For the CB-1 antagonists formulated with Invisicare, a 62% penetration rate was achieved over the same time period; In addition to these high penetration rates, these studies demonstrate that Invisicare formulations have the ability to provide sustained drug delivery over time. Data showed an average drug release of approximately 10% per hour. Building on this breakthrough, Skinvisible is confident that its proprietary technology can be applied to a broader range of GLP-1 agonists and CB-1 receptor antagonists with a molecular mass that permits transdermal penetration.

This development opens up exciting possibilities for expanding the company's portfolio of obesity-targeting formulations.